BioMarin Pharmaceutical and Ascendis Pharma have resolved all global patent disputes related to Ascendis's drug Yuviwel, including cases before the U.S. International Trade Commission. Under the agreement, Ascendis will pay BioMarin royalties of 20% on U.S. net sales and 18% on sales in the EU, Brazil, and South Korea until May 2030. This settlement includes licensing BioMarin's patents for Yuviwel's use in treating conditions like achondroplasia and hypochondroplasia, ensuring continued access to the medicine worldwide. The deal allows BioMarin to focus on further innovation in rare genetic diseases while ending ongoing litigation in multiple countries.
Zcash developers launched Zakura Common, an open-source cryptographic library that reduces private transaction creation time from over 3 seconds to less than 200 milliseconds. This upgrade makes shielded transactions on mobile devices more than 14 ti...
Bitcoin held steady between $77,580 and $78,800 despite U.S.-Iran tensions boosting oil prices nearly 2%. It outperformed gold and Nasdaq in August with a 23% gain. Large investors bought $3 billion in BTC last week, while Bitcoin ETFs saw a sharp $2...
A Fireblocks custody wallet moved $30 million worth of USD1 stablecoins on the Solana network to Binance over 15 hours, following previous transfers totaling about $66 million in the prior week. USD1 is a dollar-pegged stablecoin issued by World Libe...
Bitcoin remained stable near $63,915 on July 30 despite heightened geopolitical tensions following US strikes on Iranian targets and an 8% surge in oil prices. While US stocks fell sharply, bitcoin's price showed resilience, though about $286 million...
Ripple's legal chief Stuart Alderoty supports the CLARITY Act, claiming it could promote job growth and economic benefits in the US crypto sector. An industry-commissioned study estimates crypto directly employs 34,000 people and supports 232,000 job...
